Furthermore, it also validated that CHIP and MDM2 mediate the degradation of ERβ and ERα, respectively, via the ubiquitin–proteasome pathway, and that targeted interference with BAG2 and MDM2 may elicit therapeutic effects in endometriosis [58]. Here, BAG2 is linked to endometriosis.